The noradrenergic agent reboxetine plus the antimuscarinic hyoscine butylbromide reduces sleep apnoea severity: a double-blind, placebo-controlled, randomised crossover trial

Richard Lim, Ludovico Messineo, Ronald R Grunstein, Jayne C Carberry, Danny J Eckert, Richard Lim, Ludovico Messineo, Ronald R Grunstein, Jayne C Carberry, Danny J Eckert

Abstract

Key points: Recent animal and human physiology studies indicate that noradrenergic and muscarinic processes are key mechanisms that mediate pharyngeal muscle control during sleep. The noradrenergic agent reboxetine combined with the anti-muscarinic hyoscine butylbromide has recently been shown to improve upper airway function during sleep in healthy individuals. However, whether these findings translate to the clinically relevant patient population of people with obstructive sleep apnoea (OSA), and the effects of the agents on OSA severity, are unknown. We found that reboxetine plus hyoscine butylbromide reduced OSA severity, including overnight hypoxaemia, via increases in pharyngeal muscle responsiveness, improvements in respiratory control and airway collapsibility without changing the respiratory arousal threshold. These findings provide mechanistic insight into the role of noradrenergic and anti-muscarinic agents on upper airway stability and breathing during sleep and are important for pharmacotherapy development for OSA.

Abstract: The noradrenergic agent reboxetine combined with the anti-muscarinic hyoscine butylbromide has recently been shown to improve upper airway function during sleep in healthy individuals. However, the effects of this drug combination on obstructive sleep apnoea (OSA) severity are unknown. Accordingly, this study aimed to determine if reboxetine plus hyoscine butylbromide reduces OSA severity. Secondary aims were to investigate the effects on key upper airway physiology and endotypic traits. Twelve people with OSA aged 52 ± 13 years, BMI = 30 ± 5 kg/m2 , completed a double-blind, randomised, placebo-controlled, crossover trial (ACTRN12617001326381). Two in-laboratory sleep studies with nasal mask, pneumotachograph, epiglottic pressure sensor and bipolar fine-wire electrodes into genioglossus and tensor palatini muscles were performed separated by approximately 1 week. Each participant received either reboxetine (4 mg) plus hyoscine butylbromide (20 mg), or placebo immediately prior to sleep. Polysomnography, upper airway physiology and endotypic estimates of OSA were compared between conditions. Reboxetine plus hyoscine butylbromide reduced the apnoea/hypopnoea index by (mean ± SD) 17 ± 17 events/h from 51 ± 30 to 33 ± 22 events/h (P = 0.005) and nadir oxygen saturation increased by 6 ± 5% from 82 ± 5 to 88 ± 2% (P = 0.002). The drug combination increased tonic genioglossus muscle responsiveness during non-REM sleep (median [25th, 75th centiles]: -0.007 [-0.0004, -0.07] vs. -0.12 [-0.02, -0.40] %maxEMG/cmH2 O, P = 0.02), lowered loop gain (0.43 ± 0.06 vs. 0.39 ± 0.07, P = 0.01), and improved airway collapsibility (90 [69, 95] vs. 93 [88, 96] %eupnoea, P = 0.02), without changing the arousal threshold (P = 0.39). These findings highlight the important role that noradrenergic and muscarinic processes have on upper airway function during sleep and the potential for pharmacotherapy to target these mechanisms to treat OSA.

Keywords: pharmacotherapy; phenotyping; respiratory physiology; sleep-disordered breathing; upper airway physiology.

© 2021 The Authors. The Journal of Physiology © 2021 The Physiological Society.

References

    1. Aishah A, Lim R, Sands SA, Taranto-Montemurro L, Wellman A, Carberry JC & Eckert DJ (2021). Different antimuscarinics when combined with atomoxetine have differential effects on obstructive sleep apnea severity. J Appl Physiol (1985) 130, 1373-1382.
    1. Appleton SL, Vakulin A, Martin SA, Lang CJ, Wittert GA, Taylor AW, McEvoy RD, Antic NA, Catcheside PG & Adams RJ (2016). Hypertension is associated with undiagnosed OSA during rapid eye movement sleep. Chest 150, 495-505.
    1. Berry RB, Budhiraja R, Gottlieb DJ, Gozal D, Iber C, Kapur VK, Marcus CL, Mehra R, Parthasarathy S, Quan SF, Redline S, Strohl KP, Davidson Ward SL & Tangredi MM & American Academy of Sleep Medicine (2012). Rules for scoring respiratory events in sleep: update of the 2007 AASM manual for the scoring of sleep and associated events. Deliberations of the sleep apnea definitions task force of the american academy of sleep medicine. J Clin Sleep Med 8, 597-619.
    1. Biancardi V, Bicego KC, Almeida MC & Gargaglioni LH (2008). Locus coeruleus noradrenergic neurons and CO2 drive to breathing. Pflugers Arch 455, 1119-1128.
    1. Bonsignore MR, Suarez Giron MC, Marrone O, Castrogiovanni A & Montserrat JM (2017). Personalised medicine in sleep respiratory disorders: focus on obstructive sleep apnoea diagnosis and treatment. Eur Respir Rev 26, 170069.
    1. Dutta R, Delaney G, Toson B, Jordan AS, White DP, Wellman A & Eckert DJ (2021). A novel model to estimate key obstructive sleep apnea endotypes from standard polysomnography and clinical data and their contribution to obstructive sleep apnea severity. Ann Am Thorac Soc 18, 656-667.
    1. Eckert DJ (2018). Phenotypic approaches to obstructive sleep apnoea - New pathways for targeted therapy. Sleep Med Rev 37, 45-59.
    1. Eckert DJ, Malhotra A, Wellman A & White DP (2014). Trazodone increases the respiratory arousal threshold in patients with obstructive sleep apnea and a low arousal threshold. Sleep 37, 811-819.
    1. Eckert DJ, White DP, Jordan AS, Malhotra A & Wellman A (2013). Defining phenotypic causes of obstructive sleep apnea. Identification of novel therapeutic targets. Am J Respir Crit Care Med 188, 996-1004.
    1. Edwards BA, Connolly JG, Campana LM, Sands SA, Trinder JA, White DP, Wellman A & Malhotra A (2013). Acetazolamide attenuates the ventilatory response to arousal in patients with obstructive sleep apnea. Sleep 36, 281-285.
    1. Edwards BA, Sands SA, Eckert DJ, White DP, Butler JP, Owens RL, Malhotra A & Wellman A (2012). Acetazolamide improves loop gain but not the other physiological traits causing obstructive sleep apnoea. J Physiol 590, 1199-1211.
    1. Finnsson E, Olafsdottir GH, Loftsdottir DL, Jonsson SAE, Helgadottir H, Agustsson JS, Sands SA & Wellman A (2021). A scalable method of determining physiological endotypes of sleep apnea from a polysomnographic sleep study. Sleep 44, zsaa168.
    1. Gargaglioni LH, Hartzler LK & Putnam RW (2010). The locus coeruleus and central chemosensitivity. Respir Physiol Neurobiol 173, 264-273.
    1. Goder R, Seeck-Hirschner M, Stingele K, Huchzermeier C, Kropp C, Palaschewski M, Aldenhoff J & Koch J (2011). Sleep and cognition at baseline and the effects of REM sleep diminution after 1 week of antidepressive treatment in patients with depression. J Sleep Res 20, 544-551.
    1. Grace KP, Hughes SW & Horner RL (2013). Identification of the mechanism mediating genioglossus muscle suppression in REM sleep. Am J Respir Crit Care Med 187, 311-319.
    1. Grace KP, Hughes SW & Horner RL (2014). Identification of a pharmacological target for genioglossus reactivation throughout sleep. Sleep 37, 41-50.
    1. Hajos M, Fleishaker JC, Filipiak-Reisner JK, Brown MT & Wong EH (2004). The selective norepinephrine reuptake inhibitor antidepressant reboxetine: pharmacological and clinical profile. CNS Drug Rev 10, 23-44.
    1. Heinzer R, Vat S, Marques-Vidal P, Marti-Soler H, Andries D, Tobback N, Mooser V, Preisig M, Malhotra A, Waeber G, Vollenweider P, Tafti M & Haba-Rubio J (2015). Prevalence of sleep-disordered breathing in the general population: the HypnoLaus study. Lancet Respir Med 3, 310-318.
    1. Jordan AS, Eckert DJ, Catcheside PG & McEvoy RD (2003). Ventilatory response to brief arousal from non-rapid eye movement sleep is greater in men than in women. Am J Respir Crit Care Med 168, 1512-1519.
    1. Jordan AS, McEvoy RD, Edwards JK, Schory K, Yang CK, Catcheside PG, Fogel RB, Malhotra A & White DP (2004). The influence of gender and upper airway resistance on the ventilatory response to arousal in obstructive sleep apnoea in humans. J Physiol 558, 993-1004.
    1. Karni A, Tanne D, Rubenstein BS, Askenasy JJ & Sagi D (1994). Dependence on REM sleep of overnight improvement of a perceptual skill. Science 265, 679-682.
    1. Kennelly MJ (2010). A comparative review of oxybutynin chloride formulations: pharmacokinetics and therapeutic efficacy in overactive bladder. Rev Urol 12, 12-19.
    1. Kirkness JP, Schwartz AR, Schneider H, Punjabi NM, Maly JJ, Laffan AM, McGinley BM, Magnuson T, Schweitzer M, Smith PL & Patil SP (2008). Contribution of male sex, age, and obesity to mechanical instability of the upper airway during sleep. J Appl Physiol 104, 1618-1624.
    1. Li A & Nattie E (2006). Catecholamine neurones in rats modulate sleep, breathing, central chemoreception and breathing variability. J Physiol 570, 385-396.
    1. Lim R, Carberry JC, Wellman A, Grunstein R & Eckert DJ (2019). Reboxetine and hyoscine butylbromide improve upper airway function during nonrapid eye movement and suppress rapid eye movement sleep in healthy individuals. Sleep 42, pii: zsy261.
    1. Martins RT, Carberry JC, Wang D, Rowsell L, Grunstein RR & Eckert DJ (2020). Morphine alters respiratory control but not other key obstructive sleep apnoea phenotypes: a randomised trial. Eur Respir J 1901344, 55.
    1. Messineo L, Eckert DJ, Lim R, Chiang A, Azarbarzin A, Carter SG & Carberry JC (2020). Zolpidem increases sleep efficiency and the respiratory arousal threshold without changing sleep apnoea severity and pharyngeal muscle activity. J Physiol 598, 4681-4692.
    1. Mokhlesi B, Hagen EW, Finn LA, Hla KM, Carter JR & Peppard PE (2015). Obstructive sleep apnoea during REM sleep and incident non-dipping of nocturnal blood pressure: a longitudinal analysis of the Wisconsin Sleep Cohort. Thorax 70, 1062-1069.
    1. Neelapu BC, Kharbanda OP, Sardana HK, Balachandran R, Sardana V, Kapoor P, Gupta A & Vasamsetti S (2017). Craniofacial and upper airway morphology in adult obstructive sleep apnea patients: A systematic review and meta-analysis of cephalometric studies. Sleep Med Rev 31, 79-90.
    1. Nguyen CD, Amatoury J, Carberry JC & Eckert DJ (2017). An automated and reliable method for breath detection during variable mask pressures in awake and sleeping humans. PLoS One 12, e0179030.
    1. Osman AM, Carter SG, Carberry JC & Eckert DJ (2018). Obstructive sleep apnea: current perspectives. Nat Sci Sleep 10, 21-34.
    1. Putnam RW, Filosa JA & Ritucci NA (2004). Cellular mechanisms involved in CO2 and acid signaling in chemosensitive neurons. Am J Physiol Cell Physiol 287, C1493-C1526.
    1. Rasch B, Pommer J, Diekelmann S & Born J (2009). Pharmacological REM sleep suppression paradoxically improves rather than impairs skill memory. Nat Neurosci 12, 396-397.
    1. Ratnavadivel R, Chau N, Stadler D, Yeo A, McEvoy RD & Catcheside PG (2009). Marked reduction in obstructive sleep apnea severity in slow wave sleep. J Clin Sleep Med 5, 519-524.
    1. Sands SA, Edwards BA, Terrill PI, Taranto-Montemurro L, Azarbarzin A, Marques M, Hess LB, White DP & Wellman A (2018a). Phenotyping pharyngeal pathophysiology using polysomnography in patients with obstructive sleep apnea. Am J Respir Crit Care Med 197, 1187-1197.
    1. Sands SA, Terrill PI, Edwards BA, Taranto Montemurro L, Azarbarzin A, Marques M, de Melo CM, Loring SH, Butler JP, White DP & Wellman A (2018b). Quantifying the arousal threshold using polysomnography in obstructive sleep apnea. Sleep 41.
    1. Smith CT, Nixon MR & Nader RS (2004). Posttraining increases in REM sleep intensity implicate REM sleep in memory processing and provide a biological marker of learning potential. Learn Mem 11, 714-719.
    1. Szabo ST & Blier P (2001). Effect of the selective noradrenergic reuptake inhibitor reboxetine on the firing activity of noradrenaline and serotonin neurons. Eur J Neurosci 13, 2077-2087.
    1. Taranto-Montemurro L, Edwards BA, Sands SA, Marques M, Eckert DJ, White DP & Wellman A (2016a). Desipramine increases genioglossus activity and reduces upper airway collapsibility during non-REM sleep in healthy subjects. Am J Respir Crit Care Med 194, 878-885.
    1. Taranto-Montemurro L, Messineo L, Azarbarzin A, Vena D, Hess LB, Calianese NA, White DP, Wellman A & Sands SA (2020). Effects of the combination of atomoxetine and oxybutynin on OSA endotypic traits. Chest 157, 1626-1636.
    1. Taranto-Montemurro L, Messineo L, Sands SA, Azarbarzin A, Marques M, Edwards BA, Eckert DJ, White DP & Wellman A (2019). The combination of atomoxetine and oxybutynin greatly reduces obstructive sleep apnea severity. A randomized, placebo-controlled, double-blind crossover trial. Am J Respir Crit Care Med 199, 1267-1276.
    1. Taranto-Montemurro L, Sands SA, Edwards BA, Azarbarzin A, Marques M, de Melo C, Eckert DJ, White DP & Wellman A (2016b). Desipramine improves upper airway collapsibility and reduces OSA severity in patients with minimal muscle compensation. Eur Respir J 48, 1340-1350.
    1. Terrill PI, Edwards BA, Nemati S, Butler JP, Owens RL, Eckert DJ, White DP, Malhotra A, Wellman A & Sands SA (2015). Quantifying the ventilatory control contribution to sleep apnoea using polysomnography. Eur Respir J 45, 408-418.
    1. Tytgat GN (2007). Hyoscine butylbromide: a review of its use in the treatment of abdominal cramping and pain. Drugs 67, 1343-1357.
    1. Varga AW & Mokhlesi B (2019). REM obstructive sleep apnea: risk for adverse health outcomes and novel treatments. Sleep Breath 23, 413-423.
    1. Wang SH, Keenan BT, Wiemken A, Zang Y, Staley B, Sarwer DB, Torigian DA, Williams N, Pack AI & Schwab RJ (2020). Effect of weight loss on upper airway anatomy and the apnea-hypopnea index. The importance of tongue fat. Am J Respir Crit Care Med 201, 718-727.
    1. Weaver TE & Grunstein RR (2008). Adherence to continuous positive airway pressure therapy: the challenge to effective treatment. Proc Am Thorac Soc 5, 173-178.
    1. Wichniak A, Wierzbicka A, Walecka M & Jernajczyk W (2017). Effects of antidepressants on sleep. Curr Psychiatry Rep 19, 63.
    1. Younes M (2019). Pathogenesis of obstructive sleep apnea. Clin Chest Med 40, 317-330.

Source: PubMed

Sponsorit ja yhteistyökumppanit

Sairaudet

Huumeiden interventiot

3
Tilaa